“We are pleased the FDA has declared that supply of the only real, FDA-approved semaglutide medicines is resolved, affirming that Novo Nordisk is meeting or exceeding current and projected nationwide ...
The FDA has now resolved the shortages of Novo Nordisk and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker ...
In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., ...
The FDA announcement confirms that the U.S. supply of both prescription-only drugs now meets or exceeds the current and ...
The big pharma sector is one that’s generally fallen out of favor for many investors over the past few decades, as large ...
The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive changes.
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Novo Nordisk's (NVO) weight loss therapy Wegovy/Ozempic come out of shortage, but the FDA won't crack down on compounders ...
Many of these unlawful and unauthorized shipments were explicitly tagged for compounding, which in turn could put many ...
Novo Nordisk only prices in management's latest year guidance and underestimates the full market potential. See why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results